Medical device cytotoxicity screening is the first and most fundamental step in biocompatibility evaluation, designed to detect harmful substances that leach from device materials and damage living cells. Performed in accordance with ISO 10993-5 and related national standards, this in vitro test provides a rapid, sensitive, and cost-effective indication of biological safety before further animal or clinical testing. This article explains the principles, sample requirements, test methods, acceptance criteria, and typical applications of cytotoxicity screening for medical devices.
Technical Overview
Cytotoxicity screening is an in vitro biological test that evaluates whether a medical device or its constituent materials release substances capable of causing cell death, inhibiting cell growth, or inducing morphological changes in cultured mammalian cells. It is universally recognized as the initial biocompatibility screening test in the ISO 10993 series of standards for the biological evaluation of medical devices, as specified in ISO 10993-5 (Tests for in vitro cytotoxicity). Because cells respond rapidly and sensitively to toxic leachables such as residual monomers, plasticizers, sterilant residues, heavy metals, and degradation products, a positive cytotoxicity result frequently signals the need for material reformulation or process optimization.
The test offers several distinct advantages: it is fast (typically completed within 5 to 10 working days), reproducible, quantitative or qualitative depending on the method selected, and independent of animal models, aligning with the 3Rs principle (replacement, reduction, and refinement) of animal welfare. Regulatory authorities worldwide, including those operating under the EU Medical Device Regulation (MDR), the United States FDA framework, and China NMPA requirements, expect cytotoxicity data as part of the biological safety dossier for most device categories with patient-contacting components.
Testing Samples
Finished Medical Devices
Final manufactured products in their sterilized, ready-to-use condition represent the ideal test article, as they include all processing aids, sterilization residuals, and packaging interactions that may influence biological response. Representative devices include catheters, syringes, infusion sets, wound dressings, orthopedic implants, dental materials, and surgical instruments with patient contact.
Polymeric and Composite Materials
Raw resins, elastomers, silicone materials, polyurethane films, and composite laminates submitted during early-stage material selection. Testing materials at this phase allows developers to eliminate cytotoxic candidates before tooling and process investments are made.
Device Components and Subassemblies
Individual components such as tubing, connectors, seals, gaskets, adhesives, coatings, printing inks, and surface treatments can be isolated for testing when a root-cause investigation of device failure is required.
Primary Packaging Materials
Blister films, thermoformed trays, and container-closure systems that directly contact the device may transfer extractable substances and are therefore subject to the same screening logic.
Candidate Extracts and Process Fluids
Liquid products, lubricants, cleaning agent residues, and extracts generated under exaggerated conditions for comparative material ranking.
Testing Items
The scope of cytotoxicity screening typically encompasses the following evaluations:
- Extract-based (elution) cytotoxicity test: incubation of cultured cells with material extracts prepared under standard conditions.
- Direct contact cytotoxicity test: placement of the test article directly onto the cell monolayer to assess contact-mediated toxicity.
- Indirect contact tests: agar diffusion assay and filter diffusion assay for diffusible toxic substances when direct contact is unsuitable.
- Qualitative morphological grading: microscopical evaluation of cell morphology, vacuolization, detachment, and lysis using the ISO 10993-5 reactivity scale of Grade 0 to Grade 4.
- Quantitative viability assays: MTT reduction assay, XTT or WST colorimetric assays, neutral red uptake assay, and colony forming efficiency assay.
- Relative growth rate (RGR) calculation and determination of the 50% inhibition concentration (IC50) where dose-response characterization is required.
- Positive and negative control verification, including reagent blanks and extract medium controls, to confirm assay validity.
Testing Methods
Sample Preparation and Extraction
Test articles are prepared and extracted in accordance with ISO 10993-12. For polymeric materials, standard extraction ratios include 0.1 g of material per 1 mL of extraction medium (for irregular solids), 0.2 g/mL for elastomers in some protocols, and 6 cm² of surface area per 1 mL for films, sheets, and tubular products. Common extraction media include serum-supplemented MEM or DMEM culture medium, physiological saline, and where appropriate, water or vegetable oil. Standard extraction conditions are 37 ± 1 °C for 24 ± 2 hours, 50 ± 2 °C for 72 ± 2 hours, or 70 ± 2 °C for 24 ± 2 hours, selected on the basis of the temperature tolerance of the material and the intended clinical use conditions.
Cell System
The preferred cell line is the mouse fibroblast L929 (ATCC CCL-1), which is the reference cell type cited in ISO 10993-5. Alternative systems such as BALB/c 3T3 cells or human-derived lines may be used when scientifically justified. Cells are cultivated in logarithmic growth phase and seeded at defined densities to ensure confluence and metabolic competence at the time of dosing.
Extract (Elution) Test Procedure
Prepared extracts are applied to confluent cell monolayers, typically at 100% concentration and serial dilutions, and incubated for 24 to 48 hours at 37 °C in a humidified 5% CO₂ atmosphere. Following incubation, cultures are examined microscopically for morphological changes and then subjected to the selected quantitative endpoint.
MTT Quantitative Assay
The MTT assay measures mitochondrial dehydrogenase activity as a surrogate for cell viability. MTT reagent is added to the cultures, viable cells reduce the yellow tetrazolium salt to purple formazan crystals, which are solubilized and read spectrophotometrically at approximately 570 nm with a reference wavelength of 630 nm. Absorbance values are converted to relative viability, and the acceptance criterion specified by ISO 10993-5 is a viability of not less than 70% of the negative control for the sample to be considered non-cytotoxic.
Qualitative Grading Scale
Under microscopic evaluation, cultures are assigned reactivity grades as follows:
- Grade 0: no detectable cell lysis or reduction in cell growth, discrete intracytoplasmic granules absent or negligible.
- Grade 1: not more than 20% of cells rounded, loosely attached, or showing morphological changes; occasional lysed cells present.
- Grade 2: more than 20% but not more than 50% of cells affected; no extensive cell lysis.
- Grade 3: more than 50% but not more than 70% of cells affected, including lysed cells and significant growth inhibition.
- Grade 4: nearly complete destruction of the cell layer.
Grades 0 and 1 are generally interpreted as a pass, Grade 2 requires case-by-case judgment, and Grades 3 and 4 constitute a failure requiring investigation and corrective action.
Reference Standards
- ISO 10993-5: Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity.
- ISO 10993-12: Biological evaluation of medical devices — Part 12: Sample preparation and reference materials.
- GB/T 16886.5 and GB/T 16886.12: the Chinese national standards harmonized with the corresponding ISO documents.
- USP General Chapter <87>: In Vitro Biological Reactivity Tests (for materials and articles intended for pharmaceutical contact).
- ASTM F895 and related ASTM methods for agar diffusion and direct contact cytotoxicity evaluation of materials.
Applications
Cytotoxicity screening serves multiple functions across the medical device product lifecycle:
- Regulatory submission: generation of biocompatibility data packages for device registration with authorities such as NMPA, FDA, and notified bodies operating under the EU MDR.
- Research and development screening: rapid ranking of candidate materials, formulations, additives, and surface treatments before committing to full ISO 10993 test batteries.
- Change control: verification that material substitutions, new suppliers, modified processing parameters, or alternative sterilization methods have not introduced cytotoxic hazards.
- Root-cause investigation: isolation of the offending component when a finished device exhibits an unexpected positive result.
- Batch release and quality control: periodic extract testing of production lots for devices with high biological risk classifications.
- Supporting biological risk management: cytotoxicity results feed directly into the biological evaluation plan and risk assessment required by ISO 10993-1.
FAQ
What is the pass criterion for cytotoxicity testing?
For quantitative assays such as the MTT elution method, the sample passes when the mean cell viability is at least 70% of the negative (blank) control. For qualitative microscopy, a reactivity grade of 0 or 1 (and, in many protocols, grade 2) is considered acceptable, whereas grades 3 and 4 indicate a cytotoxic response.
How long does a cytotoxicity screening test take?
A standard elution test, including extraction (24 hours), cell incubation (24 to 48 hours), and endpoint measurement, is typically completed within 5 to 10 working days from sample receipt when cell cultures are available. Repeat testing or additional dilution series may extend the timeline.
Which cell line should be used?
The L929 mouse fibroblast line is the default reference cell type specified in ISO 10993-5 and is accepted by regulators worldwide. Other established or primary cells may be used if scientifically justified in the test report.
Can cytotoxicity testing replace other ISO 10993 tests?
No. Cytotoxicity is only one component of the biological evaluation required by ISO 10993-1. Depending on the nature and duration of body contact, additional endpoints such as sensitization, irritation, hemocompatibility, genotoxicity, and implantation testing are usually required. However, a negative cytotoxicity result is a prerequisite that de-risks and supports the overall test strategy.
What causes a positive cytotoxicity result?
Common causes include residual monomers or solvents, plasticizers and additives that migrate from polymers, inadequate removal of sterilant residues such as ethylene oxide, surface contaminants from machining or cleaning agents, and cytotoxic dyes or inks. Chemical characterization under ISO 10993-18 is often the next step in identifying the responsible extractables.
Should testing be performed in-house or by an external laboratory?
Both approaches are valid, provided the facility maintains qualified cell banks, validated assay procedures, appropriate controls, and GLP-compliant documentation. Many manufacturers engage accredited third-party laboratories with established ISO 17025 quality systems to generate data suitable for regulatory submission, particularly when independence and formal reporting are required.